UroGen Pharma Ltd. Net Cash Provided by (Used in) Financing Activities in USD from 2015 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
UroGen Pharma Ltd. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2015 to Q1 2025.
  • UroGen Pharma Ltd. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $34K.
  • UroGen Pharma Ltd. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $195M, a 66.4% increase from 2023.
  • UroGen Pharma Ltd. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $117M, a 20.4% increase from 2022.
  • UroGen Pharma Ltd. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $97.1M, a 34.3% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

UroGen Pharma Ltd. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $34K* -$54.6M Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q1 2024 $54.7M +$54M +8046% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q1 2023 $671K -$70.1M -99.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q1 2022 $70.7M +$70.7M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $4K* -$86K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q1 2020 $90K* -$163M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-13
Q1 2019 $164M +$99.3M +154% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 $64.3M +$64.4M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2017 -$108K* Jan 1, 2017 Mar 31, 2017 6-K 2018-05-15

UroGen Pharma Ltd. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $195M +$77.7M +66.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-10
2023 $117M +$19.8M +20.4% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-10
2022 $97.1M +$24.8M +34.3% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-14
2021 $72.3M +$55.8M +338% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-24
2020 $16.5M -$149M -90% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-21
2019 $165M +$98.8M +149% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-18
2018 $66.4M +$4.84M +7.85% Jan 1, 2018 Dec 31, 2018 10-K 2020-03-02
2017 $61.6M +$61.6M Jan 1, 2017 Dec 31, 2017 10-K 2020-03-02
2016 -$9K* -$21.6M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 $21.6M Jan 1, 2015 Dec 31, 2015 20-F 2018-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.